BACKGROUND: The relationship between the degree of glycaemic control and mortality remains an important topic of discussion. AIM: This study aimed to investigate this relationship. DESIGN OF STUDY: Prospective cohort study. SETTING: Primary care. METHOD: A total of 1145 patients with type 2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) in 1998. Their survival status was recorded in September 2004. Mortality ratios were calculated using standardised mortality ratios (SMRs). Associations between haemoglobin A(1c) (HbA(1c)) levels and mortality were studied with a Cox proportional hazard model. HbA(1c) levels were studied as continuous and as categorical variables. RESULTS: A total of 335 patients died after a median follow-up period of 5.8 years. The SMR (95% confidence interval [CI]) for total mortality was 1.86 (95% CI = 1.66 to 2.06) and 2.24 (95% CI = 1.91 to 2.61) for cardiovascular mortality. For each 1% increase in HbA(1c) there was a 21% increase in the hazard ratio for total mortality. When compared with the target HbA(1c) group (HbA(1c) 6.5-7%), the group with very poor glycaemic control (HbA1c >9%) had a hazard ratio of 2.21 (95% CI = 1.42 to 3.42) for total mortality. The group with normal glycaemic control (HbA(1c) <6.5%) had a hazard ratio of 1.00 (95% CI = 0.46 to 2.19) for total mortality. CONCLUSION: HbA(1c) level was associated with mortality and this effect seemed largely attributable to patients who were in really poor glycaemic control. The absence of differences in mortality in the groups with lower HbA(1c) levels supports the position that there is no basis for continually decreasing the therapeutic target HbA(1c) level in patients with type 2 diabetes mellitus.
BACKGROUND: The relationship between the degree of glycaemic control and mortality remains an important topic of discussion. AIM: This study aimed to investigate this relationship. DESIGN OF STUDY: Prospective cohort study. SETTING: Primary care. METHOD: A total of 1145 patients with type 2 diabetes were enrolled in the Zwolle OutpatientDiabetes project Integrating Available Care (ZODIAC) in 1998. Their survival status was recorded in September 2004. Mortality ratios were calculated using standardised mortality ratios (SMRs). Associations between haemoglobin A(1c) (HbA(1c)) levels and mortality were studied with a Cox proportional hazard model. HbA(1c) levels were studied as continuous and as categorical variables. RESULTS: A total of 335 patients died after a median follow-up period of 5.8 years. The SMR (95% confidence interval [CI]) for total mortality was 1.86 (95% CI = 1.66 to 2.06) and 2.24 (95% CI = 1.91 to 2.61) for cardiovascular mortality. For each 1% increase in HbA(1c) there was a 21% increase in the hazard ratio for total mortality. When compared with the target HbA(1c) group (HbA(1c) 6.5-7%), the group with very poor glycaemic control (HbA1c >9%) had a hazard ratio of 2.21 (95% CI = 1.42 to 3.42) for total mortality. The group with normal glycaemic control (HbA(1c) <6.5%) had a hazard ratio of 1.00 (95% CI = 0.46 to 2.19) for total mortality. CONCLUSION: HbA(1c) level was associated with mortality and this effect seemed largely attributable to patients who were in really poor glycaemic control. The absence of differences in mortality in the groups with lower HbA(1c) levels supports the position that there is no basis for continually decreasing the therapeutic target HbA(1c) level in patients with type 2 diabetes mellitus.
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Christoph Stettler; Sabin Allemann; Peter Jüni; Carole A Cull; Rury R Holman; Matthias Egger; Stephan Krähenbühl; Peter Diem Journal: Am Heart J Date: 2006-07 Impact factor: 4.749
Authors: Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden Journal: Ann Intern Med Date: 2004-09-21 Impact factor: 25.391
Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: John W Peabody; Enrico de Belen; Jeffrey R Dahlen; Maria Czarina Acelajado; Mary T Tran; David R Paculdo Journal: J Diabetes Sci Technol Date: 2019-07-07
Authors: Jennifer A Campbell; Alice Yan; Renee E Walker; Lance Weinhardt; Yang Wang; Rebekah J Walker; Leonard E Egede Journal: J Racial Ethn Health Disparities Date: 2020-06-25
Authors: Diewertje Sluik; Heiner Boeing; Jukka Montonen; Rudolf Kaaks; Annekatrin Lukanova; Annelli Sandbaek; Kim Overvad; Larraitz Arriola; Eva Ardanaz; Calogero Saieva; Sara Grioni; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; Annemieke M W Spijkerman; Daphne L van der A; Joline W J Beulens; Susan van Dieren; Peter M Nilsson; Leif C Groop; Paul W Franks; Olov Rolandsson; Bas Bueno-de-Mesquita; Ute Nöthlings Journal: PLoS One Date: 2012-06-13 Impact factor: 3.240
Authors: Gijs W D Landman; Jana V van Vliet-Ostaptchouk; Nanne Kleefstra; Kornelis J J van Hateren; Iefke Drion; Klaas H Groenier; Rijk O B Gans; Harold Snieder; Marten H Hofker; Henk J G Bilo Journal: Cardiovasc Diabetol Date: 2012-11-07 Impact factor: 9.951